抗凝血因子Ⅸ(F9)單克隆抗體
Anti-Coagulation Factor IX (F9) Monoclonal Antibody
HEMB; FIX; GLA Domain; PTC; Anti Hemophilic Factor B; Christmas Factor; Plasma Thromboplastic Component; Christmas Disease; Hemophilia B
- 編號(hào)UFAA840Rb02
- 物種Oryctolagus cuniculus (Rabbit，兔) 相同的名稱，不同的物種。
- 效價(jià)C2
- Ig亞型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 激發(fā)波長(zhǎng)
- 單次使用量
- 緩沖液成份磷酸鹽緩沖液（pH7.4,含有0.02% NaN3和50%甘油）
- 性狀液體
- 且適物種Homo sapiens (Human，人)
- 應(yīng)用FCM
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 25test50test 100test 200test 500test
- 價(jià)格 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià) 暫無(wú)報(bào)價(jià)
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Human HepG2 cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 10μg/ml mouse Anti-rabbit F9 Monoclonal Antibody (Catalog FAA840Rb02, red histogram) or Isotype control antibody (Catalog IS067-Mu01, green histogram), followed by 1μg/ml FITC-conjugated Anti-mouse IgG Secondary Antibody (Catalog SAA544Mu18).
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
用法
Flow cytometry: 10μg/ml;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)一年。避免反復(fù)凍融。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Oryctolagus cuniculus (Rabbit，兔) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPA840Rb03 | 凝血因子Ⅸ(F9)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA840Rb02 | 凝血因子Ⅸ(F9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA840Rb03 | 凝血因子Ⅸ(F9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA840Rb01 | 凝血因子Ⅸ(F9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA840Rb51 | 凝血因子Ⅸ(F9)多克隆抗體 | WB |
| ULAA840Rb71 | 凝血因子Ⅸ(F9)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| UMAA840Rb21 | 凝血因子Ⅸ(F9)單克隆抗體 | WB |
| UMAA840Rb22 | 凝血因子Ⅸ(F9)單克隆抗體 | WB |
| UFAA840Rb02 | 抗凝血因子Ⅸ(F9)單克隆抗體 | FCM |
| UFAA840Rb04 | 抗凝血因子Ⅸ(F9)單克隆抗體 | FCM |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Cardiovascular?Research | Loss of accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity [Pubmed:29444200] |
留言咨詢
